5-Amino-1MQ vs Semaglutide
A small-molecule NNMT inhibitor studied in animals for fat loss and NAD+ metabolism.
The revolutionary once-weekly GLP-1 medication that helps your body feel full faster and longer, leading to significant weight loss while also protecting your heart—FDA approved and backed by some of the largest clinical trials in obesity medicine history.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
5-Amino-1MQ
N/A
Semaglutide
0.5–1 mg
Frequency
5-Amino-1MQ
No human dose established
Semaglutide
Once weekly
Administration
5-Amino-1MQ
Subcutaneous injection
Semaglutide
Subcutaneous injection
Cycle length
5-Amino-1MQ
8-12 weeks (community-reported; no human trial data)
Semaglutide
Ongoing/indefinite
Onset speed
5-Amino-1MQ
Not established in humans; gradual over weeks in animal studies
Semaglutide
Moderate (1-2 weeks)
Evidence level
5-Amino-1MQ
Preclinical only (animal and lab studies; no human trials)
Semaglutide
Strong human trials (Phase 3 or FDA approved)
Benefit ratings
Fat and weight reduction
Metabolic markers
NAD+ / cellular energy
Human evidence
Weight Loss
Appetite Control
Heart Protection
Compound specifications
5-Amino-1MQ
Molecular formula
C10H11N2+ (cation); commonly supplied as the iodide salt (C10H11IN2)
Molecular weight
159.21 g/mol (cation); 286.11 g/mol (iodide salt)
Half-life
Not established in humans; preclinical rodent data suggest a few hours (compound is membrane-permeable and orally active)
Bioavailability
Orally bioavailable in animal studies (high membrane permeability shown by PAMPA and Caco-2 assays); human data not established
CAS number
42464-96-0 (salt form)
Semaglutide
Molecular formula
C187H291N45O59
Molecular weight
4113.58 g/mol
Half-life
Approximately 7 days (168 hours)
Bioavailability
89% (subcutaneous); 0.4-1% (oral, with absorption enhancer)
CAS number
910463-68-2
Dosing compared
5-Amino-1MQ
50 – 150 mg/day (community-reported, no trial)
Once daily, per community protocols · Undefined — no human study has run any duration
This is not a dose anyone established; it is the range people report using. The absence of human data here was checked rather than assumed: PubMed has no record under "5-amino-1MQ" and no clinical study of any NNMT inhibitor in people, ClinicalTrials.gov has no registered study of either the compound or the target, and no company has announced a clinical programme. The EU and WHO trial registries were not searched directly, so a trial registered only outside the US cannot be ruled out. With no human trial, there is no human safety data and no established human maximum, so there is nothing to describe any of these figures as tolerated against. It is shown as a single range rather than as starting, standard and advanced steps because no study set those steps — whether people using it escalate through them is a question about community practice that has not been checked here. The numbers that do exist are animal data only and do not convert to a human dose: mice received about 34 mg/kg a day by subcutaneous injection, 20 mg/kg three times daily for 11 days, n=9 [1]. In a dose-escalation study spanning 10 to 150 mg/kg/day, 60 mg/kg/day produced no observable adverse effects — in TWO mice [1]. Lab screening found off-target monoamine oxidase-A inhibition at higher concentrations, so caution with MAO-sensitive drugs and foods is reasonable [2], and the compound is cytotoxic to cultured pre-adipocytes at high concentration — about 40% loss of viability at 600 µM against none at 10 µM [1].
Semaglutide
Subcutaneous
4 weeks
0.25 mg
Once weekly · 4 weeks
This is the starter dose to help your body adjust. It does not lower blood sugar much on its own, so it is only used for the first 4 weeks before stepping up [5].
At least 4 weeks at each step
0.5-1 mg
Once weekly · At least 4 weeks at each step
After the starter month, the dose goes up to 0.5 mg, and can rise to 1 mg if more blood sugar control is needed. Wait at least 4 weeks before each increase [5].
Ongoing/maintenance
2-2.4 mg
Once weekly · Ongoing/maintenance
The highest weekly doses. 2 mg is the maximum for diabetes (Ozempic) [5]; up to 2.4 mg is used for weight management (Wegovy) after a slower titration.
Oral
30 days
3 mg
Once daily · 30 days
The pill form (Rybelsus) starts at 3 mg each morning for 30 days. Like the starter shot, this dose is for getting started and does not control blood sugar by itself. Take on an empty stomach with a small sip of water, 30 minutes before food or other pills [6].
30+ days
7 mg
Once daily · 30+ days
After the first 30 days, the dose increases to 7 mg once daily. This is the first dose that actively lowers blood sugar [6].
Ongoing/maintenance
14 mg
Once daily · Ongoing/maintenance
The highest pill dose, used if more blood sugar control is needed after at least 30 days at 7 mg [6].
Best suited for
5-Amino-1MQ
Fat loss research
The clearest, most repeated finding: obese mice lost body weight and fat mass on 5-Amino-1MQ without eating less [1][2]. This is the main reason people are interested — though it is animal data, not human proof.
Metabolic health support
In mice, it improved blood sugar, insulin, and liver fat [2]. Researchers see NNMT inhibition as a promising angle for metabolic syndrome [4].
NAD+ and cellular energy science
By blocking NNMT, it raises NAD+ and SAM inside cells, which supports how cells make and use energy [1][4]. This makes it interesting to people studying aging and metabolism.
Semaglutide
People with Obesity Seeking Significant Weight Loss
If your BMI is 30 or higher (or 27+ with weight-related health conditions), semaglutide is currently one of the most effective non-surgical weight loss options available. [7] Clinical trials show average weight loss of 15% of body weight—that's 30+ pounds for someone starting at 200 pounds [1].
Those Who've Struggled with Diet and Exercise Alone
Semaglutide works by changing the biological signals that drive hunger and cravings. If you've tried to lose weight through willpower alone and found yourself constantly battling hunger, this medication addresses that underlying biology rather than just telling you to eat less [3][7][13].
People with Type 2 Diabetes Needing Better Control
Originally developed for diabetes, semaglutide excellently controls blood sugar while also promoting weight loss—addressing two major health concerns simultaneously. [3][5] It can often allow people to reduce or eliminate other diabetes medications [21].
Individuals at High Cardiovascular Risk
The SELECT trial proved that semaglutide reduces heart attacks, strokes, and cardiovascular death by 20% in people with obesity and existing heart disease—even without diabetes. It's one of the few weight loss medications proven to improve hard cardiovascular outcomes [2].
Side effects
5-Amino-1MQ
Common
- No verified human side effects
- Mild nausea or headache (community-reported)
Uncommon
- Fatigue or flushing (community-reported)
Serious
- Possible off-target MAO-A effects (theoretical)
- Unknown long-term and human risks
Semaglutide
Common
- Nausea
- Constipation or Diarrhea
- Decreased Appetite
- Vomiting
Uncommon
- Gallbladder Problems
- Hair Loss (Telogen Effluvium)
Serious
- Pancreatitis
- Thyroid Tumors (Theoretical Risk)
Safety & evidence
5-Amino-1MQ
Evidence level
Preclinical only (animal and lab studies; no human trials)
FDA status
Research compound — not FDA approved
Safety overview
The honest picture: nobody has run a human safety trial on 5-Amino-1MQ, so everything below is from mice and cultured cells. In the 11-day mouse study, 9 treated animals lost 2.0 ± 0.6 g of body weight (about 5.1% from baseline) while 9 controls gained 0.6 ± 0.4 g, with no difference in food intake and no observable adverse effects reported [1]. The tolerability ceiling people quote comes from a dose-escalation study spanning 10 to 150 mg/kg/day in TWO mice, where 60 mg/kg/day produced no observable adverse effects [1] — a denominator worth seeing before treating it as a safety margin. In cultured pre-adipocytes the compound is cytotoxic at high concentration: no effect on viability at 10 µM, modest cytotoxicity from 100 to 300 µM, and roughly 40% loss of viability at 600 µM [1]. Lab screening also found off-target inhibition of monoamine oxidase-A at higher concentrations [2]. Short studies in mice cannot rule out problems that appear over months or years in people. Treat this as an experimental compound and talk to a doctor first, particularly if you take any medication.
Contraindications
- No human safety data exists — all evidence is from animals and lab work
- Pregnancy or breastfeeding
- Use with MAO-A-sensitive medications, given off-target MAO-A inhibition seen in lab screening [2]
Semaglutide
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Semaglutide has been studied in over 20,000 participants across multiple large clinical trials, making it one of the most thoroughly researched weight loss medications available. [1][2][8][9][10] The FDA approved it after rigorous review of safety data. While GI side effects are common (especially early on), serious side effects are rare. [1][7] The SELECT trial showed it actually reduces cardiovascular events, adding a safety benefit beyond just weight loss [2].
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC) [7]
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [7]
- History of serious allergic reaction to semaglutide [7]
Which is right for you?
Choose 5-Amino-1MQ if...
- Fat loss (research context)
- Metabolic health support
- NAD+ and cellular energy metabolism
Choose Semaglutide if...
- Significant weight loss
- Long-term weight management
- Cardiovascular risk reduction
- Blood sugar control